ALS patients with specific TARDBP mutations show differences in survival; patients with G298S mutations have shorter survival (27 months) compared to patients with A315T and M337V mutations (100 months) (Regal et al., 2006). The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.